TrialA Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS
Trial details
- Registry ID
- NCT05357950
- Phase
- Phase 2
NRSN
NeuroSense Therapeutics Ltd.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
2Trials in this database
5Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALSNCT05357950 | NRSN | Phase 2 | Completed | 2023-11-02Actual |
| A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.NCT06185543 | NRSN | Phase 2 | Terminated | 2025-09-30Actual |
A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.
Trial details
- Registry ID
- NCT06185543
- Phase
- Phase 2
Latest recorded trial changes
A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.
NCT06185543 · NeuroSense Therapeutics Ltd.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
20 participants (planned)
+ After
8 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Nov 2025
+ After
30 Sep 2025
Recruitment status changed
− Before
Recruiting
+ After
Terminated